Form 4: Enliven Therapeutics CFO Acquires 171,000 Stock Options

Benjamin Hohl, CFO of Enliven Therapeutics, acquired 171,000 stock options on February 6, 2025, according to a Form 4 filing with the SEC.

Summary

• Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on February 6, 2025.
• Hohl acquired 171,000 stock options with an exercise price of $22.47.
• These options vest over time, with 1/4th vesting on February 6, 2026, and the remaining 1/48th vesting monthly thereafter, contingent upon continued service.
• The options expire on February 6, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. The CFO's acquisition could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options incentivizes the CFO to remain with the company and contribute to its long-term success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing is typical for executives receiving stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by the CFO aligns his interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates